Rep. Gilbert Ray Cisneros, Jr. Buys Shares of Globus Medical, Inc. (NYSE:GMED)

Key Points

• Rep. Gilbert Ray Cisneros Jr. purchased $15,001–$50,000 of Globus Medical shares on August 19, disclosed in a September 10 filing. He also bought shares of Quanta Services and Eaton while selling positions in DoorDash, Nike, Phreesia and Lamar Advertising.
• Globus Medical reported quarterly EPS of $1.34, beating estimates of $1.10, while revenue rose 5.9% year over year to $789.61 million. The company reaffirmed fiscal 2026 EPS guidance of $4.95–$5.05.
• GMED shares opened at $74.21, below the analyst consensus price target of $101.77; analysts maintain a “Moderate Buy” consensus. Institutional investors own 95.16% of the company, while a Globus director recently sold $2.18 million of shares.

Representative Gilbert Ray Cisneros, Jr. (Democratic-California) recently bought shares of Globus Medical, Inc. (NYSE:GMED). In a filing disclosed on September 10th, the Representative disclosed that they had bought between $15,001 and $50,000 in Globus Medical stock on August 19th. The trade occurred in the Representative's "150 MAIN STREET TRUST > BANK OF AMERICA" account.

Representative Gilbert Ray Cisneros, Jr. also recently made the following trade(s):

• Sold $1,001 - $15,000 in shares of DoorDash NASDAQ: DASH on 8/28/2026.
• Purchased $15,001 - $50,000 in shares of Quanta Services NYSE: PWR on 8/27/2026.
• Purchased $15,001 - $50,000 in shares of Eaton NYSE: ETN on 8/27/2026.
• Sold $15,001 - $50,000 in shares of NIKE NYSE: NKE on 8/27/2026.
• Sold $1,001 - $15,000 in shares of Phreesia NYSE: PHR on 8/26/2026.
• Purchased $1,001 - $15,000 in shares of Wheaton Precious Metals NYSE: WPM on 8/26/2026.
• Purchased $1,001 - $15,000 in shares of Walmart NASDAQ: WMT on 8/26/2026.
• Purchased $1,001 - $15,000 in shares of The Goldman Sachs Group NYSE: GS on 8/26/2026.
• Sold $15,001 - $50,000 in shares of Lamar Advertising NASDAQ: LAMR on 8/25/2026.
• Sold $1,001 - $15,000 in shares of Phreesia NYSE: PHR on 8/25/2026.

Globus Medical Trading Up 0.9%

Shares of NYSE:GMED opened at $74.21 on Friday. The firm has a market capitalization of $9.96 billion, a PE ratio of 18.98, a PEG ratio of 1.18 and a beta of 0.95. Globus Medical, Inc. has a 1-year low of $54.15 and a 1-year high of $101.40. The business's 50 day moving average is $80.40 and its 200-day moving average is $83.82.

Globus Medical (NYSE:GMED - Get Free Report) last posted its quarterly earnings results on Thursday, August 6th. The medical device company reported $1.34 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.10 by $0.24. The firm had revenue of $789.61 million during the quarter, compared to analyst estimates of $782.88 million. Globus Medical had a net margin of 17.02% and a return on equity of 14.57%. The company's quarterly revenue was up 5.9% compared to the same quarter last year. During the same quarter in the prior year, the business posted $0.86 earnings per share. Globus Medical has set its FY 2026 guidance at 4.950-5.050 EPS. On average, sell-side analysts predict that Globus Medical, Inc. will post 4.99 EPS for the current year.

Hedge Funds Weigh In On Globus Medical

Institutional investors have recently modified their holdings of the stock. California State Teachers Retirement System grew its stake in Globus Medical by 7,827.7% in the second quarter. California State Teachers Retirement System now owns 10,326,607 shares of the medical device company's stock valued at $815,905,000 after purchasing an additional 10,196,347 shares in the last quarter. Invesco Ltd. boosted its holdings in shares of Globus Medical by 1,235.2% in the 4th quarter. Invesco Ltd. now owns 3,886,405 shares of the medical device company's stock valued at $339,322,000 after buying an additional 3,595,339 shares during the last quarter. Bank of Montreal Can grew its stake in shares of Globus Medical by 15,317.1% in the fourth quarter. Bank of Montreal Can now owns 3,373,260 shares of the medical device company's stock valued at $294,519,000 after buying an additional 3,351,380 shares in the last quarter. Alliancebernstein L.P. grew its stake in shares of Globus Medical by 1,303.9% in the third quarter. Alliancebernstein L.P. now owns 2,055,183 shares of the medical device company's stock valued at $117,700,000 after buying an additional 1,908,795 shares in the last quarter. Finally, Fuller & Thaler Asset Management Inc. acquired a new position in Globus Medical during the fourth quarter worth $90,411,000. 95.16% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of equities research analysts recently issued reports on GMED shares. BMO Capital Markets assumed coverage on shares of Globus Medical in a research report on Wednesday, July 8th. They set an "outperform" rating and a $94.00 target price for the company. Truist Financial reduced their price target on shares of Globus Medical from $115.00 to $100.00 and set a "buy" rating on the stock in a research report on Thursday, July 16th. Weiss Ratings reaffirmed a "hold (c+)" rating on shares of Globus Medical in a research note on Monday, July 13th. Piper Sandler dropped their price objective on shares of Globus Medical from $115.00 to $100.00 and set an "overweight" rating for the company in a report on Monday, June 15th. Finally, Zacks Research upgraded shares of Globus Medical from a "hold" rating to a "strong-buy" rating in a research note on Monday, August 10th. Three research analysts have rated the stock with a Strong Buy rating, nine have issued a Buy rating and five have issued a Hold rating to the company's stock. According to data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and an average target price of $101.77.

Insider Transactions at Globus Medical

In other Globus Medical news, Director Stephen Zarrilli sold 25,000 shares of the stock in a transaction on Tuesday, August 18th. The shares were sold at an average price of $87.04, for a total value of $2,176,000.00. Following the completion of the sale, the director owned 25,000 shares in the company, valued at $2,176,000. This trade represents a 50.00% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. Company insiders own 18.38% of the company's stock.

About Representative Cisneros

Gil Cisneros (Democratic Party) is a member of the U.S. House, representing California's 31st Congressional District. He assumed office on January 3, 2025. His current term ends on January 3, 2027. Cisneros (Democratic Party) is running for re-election to the U.S. House to represent California's 31st Congressional District. He declared candidacy for the 2026 election. Gil Cisneros served in the U.S. Navy as a supply officer from 1994 to 2004. Cisneros earned a bachelor's degree in political science from George Washington University in 1994, a master's in business administration from Regis University in 2002, and a master's degree in urban education policy from Brown University in 2015. His career experience includes working as a logistics manager for Frito-Lay. In 2010, Cisneros won the lottery and became involved in activism and philanthropy, founding a scholarship program for local high school students. In 2021, President Joe Biden (D) appointed Cisneros as under secretary of defense for personnel and readiness.

About Globus Medical

Globus Medical, Inc NYSE: GMED is a medical device company that develops, manufactures and markets musculoskeletal solutions for surgeons, hospitals and patients. Its primary focus is spinal surgery, supported by a portfolio of implants, instruments and enabling technologies designed to assist with procedures involving the cervical, thoracic and lumbar spine.

The company's products include spinal fusion systems, interbody devices, deformity correction systems, biologics and surgical instruments.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.